Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  cytarabine
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 1229 for your search:
Start Over
Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 15 to 65
Sponsor: Other
Protocol IDs: GMALL03, NCT00199004
AML2003 - Standard-Therapy vs Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 16 to 60
Sponsor: Other
Protocol IDs: MK1-95, NCT00180102
Therapy of Acute Myeloid Leukemia in Patients Over the Age of 60 : DA Versus Mitoxantrone With Intermittent AraC
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 60 and over
Sponsor: Other
Protocol IDs: AML_GT60_DD, NCT00180167
PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation
Phase: Phase IV
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20050100, NCT00352703
Treatment of Acute Myeloblastic Leukemia in Younger Patients
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 65 and under
Sponsor: Other
Protocol IDs: AML99<=65 años, NCT00390715
Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005)
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 0 to 75
Sponsor: Other
Protocol IDs: LPA 2005, NCT00408278
Oral Zinc Therapy for the Prevention of Mucositis
Phase: Phase IV
Type: Supportive care, Treatment
Status: Completed
Age: 18 to 70
Sponsor: Other
Protocol IDs: SHEBA-06-4196-MKM-CTIL, NCT00449592
PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 15 and over
Sponsor: Other
Protocol IDs: LAL-RI/96, NCT00494897
Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO)
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: LAP-R2007, NCT00504764
LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 65 and under
Sponsor: Other
Protocol IDs: LAL-Ph-2000, NCT00526305
LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 16 and under
Sponsor: Other
Protocol IDs: LAL-AR-N-2005, NCT00526409
AMENO-2: Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors
Phase: Phase IV
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2006-00055-18, NCT00415103
LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: Any age
Sponsor: Other
Protocol IDs: PETHEMA-LAM07, NCT01041040
Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 to 60
Sponsor: Other
Protocol IDs: RJ-2010-56, NCT01358253
Intensified Conditioning Regimen With High-Dose-Etoposide for Allo-HSCT for Adult Acute Lymphoblastic Leukemia
Phase: Phase IV
Type: Treatment
Status: Closed
Age: 16 to 65
Sponsor: Other
Protocol IDs: HDE-ALL-2011, NCT01457040
3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia
Phase: Phase IV
Type: Treatment
Status: Closed
Age: 15 to 60
Sponsor: Other
Protocol IDs: AML-01.10, NCT01587430
Phase II/III Randomized Study of Monoclonal Antibody HuM195 As Maintenance Therapy in Elderly Patients with Acute Myeloid Leukemia in Complete Remission Following Chemotherapy (Summary Last Modified 12/98)
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 60 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PDL-3-251, MSKCC-93131, NCI-V94-0469
Phase II-III VCR/PRED/L-ASP Induction, CNS Therapy plus MTX vs 6-MP/MTX vs 6-MP/MTX/CTX vs 6-MP/MTX/CTX/ARA-C for Pediatric ALL
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: under 18
Sponsor:
Protocol IDs: SJCRH-ALL-TT-8
Phase II/III Chemotherapy with DNM/ARA-C Induction and DNM/ARA-C/TG, DNM/AZC, and ARA-C/TG Maintenance for Acute Myelogenous Leukemia
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: under 60
Sponsor:
Protocol IDs: NCI-D81-018-590, DFCI-80035
Phase II/III Autologous Stem Cell Reinfusion Following ARA-C/BCNU for CML in Blast Crisis
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: no age specified
Sponsor:
Protocol IDs: NCI-D82-018-544, DFCI-80051, DFCI-CML
Phase II/III Consolidation Chemotherapy with VP-16/AMSA/AZC Following Induction with DNM/ARA-C/TG for Adult Primary or Secondary Leukemia
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: NCI-D82-051-605
Phase II/III Pilot Combination Chemotherapy and Radiotherapy for Previously Untreated Childhood ALL with Poor Prognosis
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: under 21
Sponsor: NCI
Protocol IDs: CCG-192P
Phase II/III Study of Induction with ARA-C/ADR plus Intensive Consolidation with Various Combinations of ADR, ARA-C, and AMSA for AML
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: physiologic 70 and under
Sponsor: NCI
Protocol IDs: RPMI-PPC-744, NCI-T83-0960D
Start Over